Search results
Nov 13, 2019 · Eva González-Barca, MD PhD 4 Department of Hematology, Institut Catalá d'Oncologia (ICO), Hospital Duran i Reynals, IDIBELL, Barcelona, Spain Search for other works by this author on:
- Efficacy and Safety of Ibrutinib in Combination with ...
Conclusion: In indolent clinical forms of MCL frontline...
- Efficacy and Safety of Ibrutinib in Combination with ...
Eva González-Barca's 196 research works with 4,106 citations and 9,566 reads, including: Artificial intelligence classifies and predicts the outcome of primary CNS and nodal large B-cell...
Eva María González Fernández (born 5 November 1980) is a Spanish actress, tv host and beauty pageant titleholder who represented her country at the Miss Universe 2003 pageant.
Contributors: Eva Gonzalez Barca; Laura Tomás‐Roca; Anna Esteve; Marta Rodriguez; Lucía Gato; Ruth Alonso‐Alonso; Alejandro Martin Garcia‐Sancho; Raul Cordoba; Anna Monter‐Rovira; Mariana Bastos‐Oreiro et al.
Eva González Barca's 66 research works with 621 citations and 4,012 reads, including: ABCL-482 Five-Year Subgroup Analysis of Tafasitamab + Lenalidomide From the Phase II L-MIND Study in...
Tafasitamab (MOR208) is an Fc-enhanced, humanised, anti-CD19 monoclonal antibody that has shown preclinical and single-agent activity in patients with relapsed or refractory B-cell malignancies. Preclinical data suggested that tafasitamab might act synergistically with lenalidomide.
Nov 13, 2019 · Conclusion: In indolent clinical forms of MCL frontline ibrutinib in combination with rituximab has a high efficacy, including undetectable MRD in the majority of cases, with a predictable toxicity profile.
